Valeant Pharmaceuticals Intl Inc  

(Public, NYSE:VRX)   Watch this stock  
Find more results for VRX
12.93
-0.38 (-2.85%)
After Hours: 12.92 -0.01 (-0.08%)
May 24, 6:56PM EDT  
NYSE real-time data - Disclaimer
Currency in USD
Range 12.74 - 13.34
52 week 8.31 - 32.74
Open 13.26
Vol / Avg. 19.75M/25.87M
Mkt cap 4.36B
P/E     -
Div/yield     -
EPS -4.04
Shares 341.19M
Beta -0.15
Inst. own 58%
Aug 8, 2017
Q2 2017 Valeant Pharmaceuticals International Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jun 7, 2017
Valeant Pharmaceuticals International Inc at Jefferies Healthcare Conference - 8:30AM EDT - Add to calendar
May 22, 2017
Valeant Pharmaceuticals International Inc at UBS Global Healthcare Conference - Webcast
May 17, 2017
Valeant Pharmaceuticals International Inc at Bank of America Merrill Lynch Healthcare Conference - Webcast
May 9, 2017
Q1 2017 Valeant Pharmaceuticals International Inc Earnings Release
May 9, 2017
Q1 2017 Valeant Pharmaceuticals International Inc Earnings Call - Webcast
May 2, 2017
Valeant Pharmaceuticals International Inc Annual Shareholders Meeting - Webcast
Mar 15, 2017
Valeant Pharmaceuticals International Inc at Barclays Global Healthcare Conference
Mar 2, 2017
Valeant Pharmaceuticals International Inc at Deutsche Bank Pharma One-on-One Day
Feb 28, 2017
Q4 2016 Valeant Pharmaceuticals International Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin 29.82% -24.89%
Operating margin 6.97% -5.85%
EBITD margin - 41.49%
Return on average assets 5.88% -5.21%
Return on average equity 71.51% -53.16%
Employees 21,500 -
CDP Score - D

Address

Laval, 2150 Saint-Elzear Blvd W
LAVAL, QC H7L 4A8
Canada
+1-514-7446792 (Phone)
+1-514-7446272 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It operates through two segments: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses on primarily on branded generics, OTC products and medical devices. Its pharmaceutical products include Xifaxan, Solodyn and Glumetza. Its OTC products include PreserVision, Biotrue and Boston. Its other generic products include Latanoprost and Metronidazole. Its ophthalmic surgical products include intraocular lenses, such as Akreos, enVista, Crystalens and Trulign.

Officers and directors

Joseph C. Papa Chairman of the Board, Chief Executive Officer
Age: 61
Bio & Compensation  - Reuters
Paul S. Herendeen Chief Financial Officer, Executive Vice President
Age: 61
Bio & Compensation  - Reuters
Christina Ackermann Executive Vice President, General Counsel
Age: 52
Bio & Compensation  - Reuters
Thomas J. Appio Executive Vice President, Company Group Chairman, International
Age: 55
Bio & Compensation  - Reuters
William D. Humphries Executive Vice President, Company Group Chairman, Dermatology
Age: 50
Bio & Compensation  - Reuters
Thomas W. Ross Sr Lead Independent Director
Age: 66
Bio & Compensation  - Reuters
William A. Ackman Independent Director
Age: 50
Bio & Compensation  - Reuters
Richard U. DeSchutter Independent Director
Age: 76
Bio & Compensation  - Reuters
Fredric N. Eshelman Independent Director
Age: 68
Bio & Compensation  - Reuters
Stephen Fraidin Independent Director
Age: 76
Bio & Compensation  - Reuters